[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559690":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":32,"studyPopulation":35,"armGroups":36,"interventions":47,"overallOfficials":32,"centralContacts":57,"locations":63,"responsibleParty":82,"collaborators":86,"id":90,"slug":32,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":32,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":32,"enrollmentInfo":98,"targetDuration":32,"studyType":101,"phases":32,"briefSummary":102,"conditions":103,"keywords":32,"overallStatus":65,"whyStopped":32,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"The primary endpoint is the risk of MACE within 1 year of follow-up","MACE was defined as the composite of non-fatal myocardial infarction, non-fatal ischemic stroke, all-cause mortality, or any coronary revascularization. Coronary revascularization was limited to procedures occurring at least two weeks after the index date, including PCI and CABG","12 months",[14,17],{"measure":15,"description":15,"timeFrame":16},"Percentage reduction of LDL-C levels at 1-month follow-up from baseline","1 month",{"measure":18,"description":19,"timeFrame":16},"Proportion of patient who achieved LDL-C goal (\u003C1.4mmol\u002FL) at 1-month follow-up","Proportion of patient who achieved LDL-C goal (\\\u003C1.4mmol\u002FL) at 1-month follow-up",[21,23,25,28],{"measure":22,"description":22,"timeFrame":12},"Association between ACS pathway optimization participation and MACE within 1 year follow-up",{"measure":24,"description":24,"timeFrame":16},"Association between ACS pathway optimization participation and LDL-C goal attainment rate at 1-month follow-up",{"measure":26,"description":26,"timeFrame":27},"Percentage reduction of LDL-C levels at 3-month, 6-month follow-up from baseline (if have enough follow-up data on lab test)","3 months, 6 months",{"measure":29,"description":30,"timeFrame":27},"LDL-C goal attainment rate (\u003C1.4mmol\u002FL) at 3-month, 6-month follow-up (if have enough follow-up data on lab test)","LDL-C goal attainment rate (\\\u003C1.4mmol\u002FL) at 3-month, 6-month follow-up (if have enough follow-up data on lab test)",{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":33,"timePerspective":34,"maskingInfo":32},null,"COHORT","RETROSPECTIVE","Data from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit. Patients prescribed with evolocumab at any time will be excluded.",[37,42],{"label":38,"type":32,"description":39,"interventionNames":40},"intervention group","patients were treated with alirocumab 75mg combined with statin ± ezetimibe",[41],"Drug: alirocumab 75mg\u002F2week",{"label":43,"type":32,"description":44,"interventionNames":45},"control group","patients were treated with statin ± ezetimibe only",[46],"Drug: statin ± ezetimibe",[48,53],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":32},"DRUG","alirocumab 75mg\u002F2week","patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference",[38],{"type":49,"name":54,"description":55,"armGroupLabels":56,"otherNames":32},"statin ± ezetimibe","patients will be censored at initiation of alirocumab during the follow up visit",[43],[58],{"name":59,"role":60,"phone":61,"phoneExt":32,"email":62},"Dandan Li, Dr.","CONTACT","+86 13810545564","lidandan5564@163.com",[64],{"facility":5,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":72,"coordinates":73},"Point",[74,75],116.39723,39.9075,{"lat":75,"lon":74},[78],{"name":79,"role":60,"phone":80,"phoneExt":81,"email":62},"Dandan Li, MD","13810545564","86",{"type":83,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Yun Dai Chen","professor",[87],{"name":88,"class":89},"Sanofi","INDUSTRY","100559690",false,"NCT06567418","Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients","Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients: A Database-based Retrospective Analysis","Inclusion Criteria:\n\n* Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.\n* Patients aged 18 years or older.\n* Patients who received Alirocumab 75 mg in combination with statin therapy ± Ezetimibe as the intervention group, and those treated exclusively with statin therapy ± Ezetimibe as the control group, either during hospitalization or at discharge.\n* Patients with at least one follow-up record.\n\nExclusion Criteria:\n\n* Patients who received Evolocumab treatment at any time.\n* Patients who received Inclisiran treatment at any time.","ALL","18 Years",{"count":99,"type":100},10000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. The main question it aims to answer is:\n\nwhether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting.\n\nData from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit.",[104],"Acute Coronary Syndrome","2024-08-20",{"date":107,"type":108},"2024-08-22","ACTUAL",{"date":110,"type":108},"2024-08-01",{"date":112,"type":100},"2025-01-31",{"name":84,"class":6},1]